Showing results (201-210 of 211) with videos related to
Sort By:
Pageof 22
Clinical Therapeutics|June 11, 2004
A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosisJ Theodore Phillips, George Rice, Elliot Frohman, et al.Cancer Research|October 18, 2002
Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotinZhengsheng Yao, Meili Zhang, Donald B Axworthy, et al.Neurology|February 15, 2015
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM studyDavid H Miller, Robert J Fox, J Theodore Phillips, et al.Neurology|March 29, 2019
Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practiceDevangi Mehta, Catherine Miller, Douglas L Arnold, et al.Archives of Neurology|October 12, 2005
Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectationsElliot M Frohman, Olaf Stüve, Eva Havrdova, et al.Archives of Neurology|February 14, 2007
Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventionsOlaf Stüve, Christina M Marra, Petra D Cravens, et al.Archives of Neurology|July 14, 2010
Translational research in neurology and neuroscience 2010: multiple sclerosisOlaf Stüve, Bernd C Kieseier, Bernhard Hemmer, et al.Journal of Bacteriology|December 11, 2007
Analysis of genetic relatedness of Haemophilus influenzae isolates by multilocus sequence typingAlice L Erwin, Sara A Sandstedt, Paul J Bonthuis, et al.Journal of Neurology|March 25, 2009
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINELMichael Hutchinson, Ludwig Kappos, Peter A Calabresi, et al.Annals of Neurology|August 19, 2007
Health-related quality of life in multiple sclerosis: effects of natalizumabRichard A Rudick, Deborah Miller, Steve Hass, et al.Pageof 22